<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>AlphaFold2 |</title><link>https://muziouyang.com/tags/alphafold2/</link><atom:link href="https://muziouyang.com/tags/alphafold2/index.xml" rel="self" type="application/rss+xml"/><description>AlphaFold2</description><generator>HugoBlox Kit (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Tue, 01 Sep 2026 00:00:00 +0000</lastBuildDate><image><url>https://muziouyang.com/media/icon_hu_1c0e9cb08cfb822a.png</url><title>AlphaFold2</title><link>https://muziouyang.com/tags/alphafold2/</link></image><item><title>Reproduction of the CLAIRE de novo protein-binder design pipeline</title><link>https://muziouyang.com/projects/claire-binder-design/</link><pubDate>Tue, 01 Sep 2026 00:00:00 +0000</pubDate><guid>https://muziouyang.com/projects/claire-binder-design/</guid><description>&lt;p&gt;&lt;strong&gt;A computational project&lt;/strong&gt; — independent work alongside my wet-lab dissertation.
I reproduced the CLAIRE small-molecule binder-design pipeline end-to-end, then
pushed it onto two targets it had never been run on.&lt;/p&gt;
&lt;svg viewBox="0 0 900 190" role="img" aria-label="The CLAIRE pipeline: a target ligand passes through Rosetta motif matching, ProteinMPNN sequence design and AlphaFold2 validation to produce binder candidates" style="width:100%;height:auto;margin:2rem 0;color:inherit"&gt;
&lt;defs&gt;
&lt;marker id="ar" markerWidth="9" markerHeight="9" refX="8" refY="4.5" orient="auto"&gt;
&lt;path d="M0,1 L8,4.5 L0,8" fill="none" stroke="currentColor" stroke-width="1.4" opacity=".55"/&gt;
&lt;/marker&gt;
&lt;/defs&gt;
&lt;g font-family="ui-sans-serif,system-ui,sans-serif" text-anchor="middle"&gt;
&lt;g opacity=".9"&gt;
&lt;rect x="4" y="44" width="150" height="76" rx="10" fill="currentColor" fill-opacity=".05" stroke="currentColor" stroke-opacity=".28"/&gt;
&lt;text x="79" y="72" font-size="14" font-weight="600" fill="currentColor"&gt;Target ligand&lt;/text&gt;
&lt;text x="79" y="92" font-size="11.5" fill="currentColor" opacity=".7"&gt;progesterone&lt;/text&gt;
&lt;text x="79" y="107" font-size="11.5" fill="currentColor" opacity=".7"&gt;thalidomide · 4-OHT&lt;/text&gt;
&lt;/g&gt;
&lt;line x1="160" y1="82" x2="196" y2="82" stroke="currentColor" stroke-width="1.4" opacity=".55" marker-end="url(#ar)"/&gt;
&lt;g&gt;
&lt;rect x="202" y="44" width="160" height="76" rx="10" fill="currentColor" fill-opacity=".05" stroke="currentColor" stroke-opacity=".28"/&gt;
&lt;text x="282" y="72" font-size="14" font-weight="600" fill="currentColor"&gt;Rosetta&lt;/text&gt;
&lt;text x="282" y="92" font-size="11.5" fill="currentColor" opacity=".7"&gt;motif generation&lt;/text&gt;
&lt;text x="282" y="107" font-size="11.5" fill="currentColor" opacity=".7"&gt;and matching&lt;/text&gt;
&lt;/g&gt;
&lt;line x1="368" y1="82" x2="404" y2="82" stroke="currentColor" stroke-width="1.4" opacity=".55" marker-end="url(#ar)"/&gt;
&lt;g&gt;
&lt;rect x="410" y="44" width="160" height="76" rx="10" fill="currentColor" fill-opacity=".05" stroke="currentColor" stroke-opacity=".28"/&gt;
&lt;text x="490" y="72" font-size="14" font-weight="600" fill="currentColor"&gt;ProteinMPNN&lt;/text&gt;
&lt;text x="490" y="92" font-size="11.5" fill="currentColor" opacity=".7"&gt;sequence design&lt;/text&gt;
&lt;/g&gt;
&lt;line x1="576" y1="82" x2="612" y2="82" stroke="currentColor" stroke-width="1.4" opacity=".55" marker-end="url(#ar)"/&gt;
&lt;g&gt;
&lt;rect x="618" y="44" width="160" height="76" rx="10" fill="currentColor" fill-opacity=".05" stroke="currentColor" stroke-opacity=".28"/&gt;
&lt;text x="698" y="72" font-size="14" font-weight="600" fill="currentColor"&gt;AlphaFold2&lt;/text&gt;
&lt;text x="698" y="92" font-size="11.5" fill="currentColor" opacity=".7"&gt;self-consistency&lt;/text&gt;
&lt;text x="698" y="107" font-size="11.5" fill="currentColor" opacity=".7"&gt;validation&lt;/text&gt;
&lt;/g&gt;
&lt;line x1="784" y1="82" x2="820" y2="82" stroke="currentColor" stroke-width="1.4" opacity=".55" marker-end="url(#ar)"/&gt;
&lt;text x="862" y="78" font-size="12.5" font-weight="600" fill="currentColor"&gt;binder&lt;/text&gt;
&lt;text x="862" y="95" font-size="12.5" font-weight="600" fill="currentColor"&gt;candidates&lt;/text&gt;
&lt;text x="450" y="22" font-size="11.5" fill="currentColor" opacity=".55"&gt;environment built from scratch — Rosetta · PyRosetta · ColabFold&lt;/text&gt;
&lt;text x="450" y="166" font-size="11.5" fill="currentColor" opacity=".55"&gt;a latent file-naming defect in the original codebase found and fixed here&lt;/text&gt;
&lt;line x1="282" y1="140" x2="282" y2="152" stroke="currentColor" stroke-width="1.2" opacity=".35"/&gt;
&lt;line x1="282" y1="152" x2="450" y2="152" stroke="currentColor" stroke-width="1.2" opacity=".35"/&gt;
&lt;/g&gt;
&lt;/svg&gt;
&lt;h2 id="three-targets-not-one"&gt;Three targets, not one&lt;/h2&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th&gt;Target&lt;/th&gt;
&lt;th&gt;Why this one&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td&gt;Progesterone&lt;/td&gt;
&lt;td&gt;the repository&amp;rsquo;s built-in example — a correctness baseline&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;Thalidomide&lt;/td&gt;
&lt;td&gt;generalization test&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;4-Hydroxytamoxifen (4-OHT)&lt;/td&gt;
&lt;td&gt;generalization test&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;The latter two were chosen deliberately: their polar-handle configurations are
chemically distinct enough to probe generalization rather than repeat a known
result.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;All three produced AlphaFold2-self-consistent candidates — best case pLDDT 94.1
at 0.62 Å RMSD.&lt;/strong&gt;&lt;/p&gt;
&lt;h2 id="why-it-matters-to-my-own-work"&gt;Why it matters to my own work&lt;/h2&gt;
&lt;p&gt;My dissertation designs bioPROTACs, which need a binding domain against their
target — so the binder is the limiting reagent, and borrowing one confines you to
targets somebody has already solved. Designing binders directly is how that
constraint comes off.&lt;/p&gt;
&lt;h2 id="related-testing-the-generalizability-of-a-multistate-design-method-on-kras"&gt;Related: testing the generalizability of a multistate design method on KRAS&lt;/h2&gt;
&lt;p&gt;I extracted the computational recipe of &lt;strong&gt;Guo et al. (Science, 2025)&lt;/strong&gt; from the
primary literature and built a three-layer framework to test whether it transfers
to the Ras superfamily:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Calibration&lt;/strong&gt; — T35S, a known state-switching mutant: does the diagnostic
detect what it claims to?&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Clinical noise&lt;/strong&gt; — G12D, G12C: does it fire on any substitution?&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Application&lt;/strong&gt; — the hypervariable-region mutation from my own dissertation.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;The first two layers are what make the third worth believing. This also meant
rebuilding the simulation system in AMBER after diagnosing that a prior model was
nucleotide-free — the replacement is GppNHp- and Mg²⁺-bound, with de novo
parameterization for the ligand and the farnesylated cysteine anchor.&lt;/p&gt;
&lt;h2 id="toolchain"&gt;Toolchain&lt;/h2&gt;
&lt;p&gt;Rosetta/PyRosetta · ProteinMPNN · AlphaFold2/ColabFold · GROMACS · AMBER/AmberTools
· OpenMM · CHARMM-GUI · antechamber, AM1-BCC, GAFF2 · Python · Linux and cloud GPU&lt;/p&gt;</description></item></channel></rss>